Subscribe

David Weinstein, MD

Senior vice president, clinical development, Passage Bio

Articles by David Weinstein, MD

David Weinstein, MD

David Weinstein, MD, on Delivering Gene Therapy Directly to the Brain

ByDavid Weinstein, MD

June 26th 2022

The senior vice president of clinical development at Passage Bio discussed intracisternal magna administration of PBGM01.

David Weinstein, MD

Cautious Optimism for GM1 Gangliosidosis Gene Therapy: David Weinstein, MD

ByDavid Weinstein, MD

March 10th 2022

The senior vice president of clinical development at Passage Bio discussed biomarker activity seen in the IMAGINE-1 trial.

David Weinstein, MD

Achieving Developmental Milestones With GM1 Gangliosidosis Gene Therapy: David Weinstein, MD

ByDavid Weinstein, MD

February 11th 2022

The senior vice president of clinical development at Passage Bio discussed new data from the IMAGINE-1 trial presented at WORLDSymposium.

Latest Updated Articles

Trending on CGTlive®

Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial

Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation

Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025

FDA Picks Abeona’s XLRS Gene Therapy ABO-503 for RDEA Pilot Program

BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again

© 2025 MJH Life Sciences^®

All rights reserved.